Myeloproliferative Neoplasms | Specialty

Frontline Therapy for Polycythemia Vera

July 9th 2019

Suspecting Polycythemia Vera: Challenges in Diagnosis

July 9th 2019

Diagnosing Polycythemia Vera

July 9th 2019

Differentiating Between Myeloproliferative Neoplasms

July 9th 2019

Overview of Myeloproliferative Neoplasms

July 9th 2019

Expert Hopeful to Add Novel Agents to MPN Armamentarium

July 3rd 2019

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

FDA Grants Momelotinib Fast Track Designation in Myelofibrosis

June 5th 2019

The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Expert Expands on Implications of Molecular Targets in Myelofibrosis

May 29th 2019

Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with myelofibrosis to determine the value of mutational profiling in predicting outcomes after transplant.

Dr. Kambhampati on Interferon and Novel Agents in MPNs

March 12th 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.

FDA Grants Fedratinib Priority Review for Myelofibrosis

March 5th 2019

The FDA has granted a priority review designation to a new drug application for fedratinib as a treatment for patients with myelofibrosis.

Newer Interferon Agents and Other Novel Treatments Propel MPN Paradigm

March 5th 2019

Suman A. Kambhampati, MD, discusses emerging data in myeloproliferative neoplasms and what is coming on the horizon.

Pegylated Interferon Formulations Shake Up MPN Treatment

February 26th 2019

Abdulraheem Yacoub, MD, discusses the development of interferon and its current role in the management of patients with myeloproliferative neoplasms.

MPNs Pioneer Highlights Long-Lasting Role of Interferon

February 22nd 2019

Richard T. Silver, MD, discusses the history of interferon and shares insight on why the drug still holds its place in the treatment of patients with MPNs.

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

November 26th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.

Unmet Needs and Future Directions in Treating MPNs

July 10th 2018

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

July 10th 2018

Treating Anemia With Luspatercept in MDS

July 10th 2018

Polycythemia Vera: Novel JAK Inhibitors

July 10th 2018

Ruxolitinib's Role in Treating Myelofibrosis

July 10th 2018

Myelofibrosis: Diagnosis and Risk Stratification

July 10th 2018